[Chirality and drugs].
The two enantiomers of a chiral drug may have vastly different pharmacodynamic and pharmacokinetic properties. As a result, the research and development of chiral drugs raises specific problems some of which are discussed here. Thus, various pharmacokinetic interactions may involve two enantiomers, as seen for example when one enantiomer inhibits the metabolism of the other and modifies its effects. A different situation occurs when a third compound stereoselectively inhibits the metabolism of one of the two enantiomers. Another problem examined here results from the lack of configurational stability of some chiral drugs, a little known phenomenon whose consequences can be of pharmacological or pharmaceutical significance depending on the rate of the reaction of racemization or epimerisation. In-depth investigations are needed before choosing between a eutomer or a racemate.
Institut de chimie thérapeutique, BEP, Université de Lausanne, CH-1015 Lausanne-Dorigny. Bernard.Testa@ICT.UNIL.CH.
B
B
Testa
M
M
Reist
P A
PA
Carrupt
D004358:Drug Therapy; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D010599:Pharmacokinetics; D013237:Stereoisomerism
D004364:Pharmaceutical Preparations